Skip to main content
. 2018 Feb 1;25(2):153–169. doi: 10.5551/jat.41095

Supplementry Fig. 1.

Supplementry Fig. 1.

Comparison of CEC and AREA at baseline and follow-up period in patients who did not take any lipid-lowering drugs at baseline (left), patients who did not smoke at follow-up (FU) (center), and patients who did not take angiotensin-converting enzyme inhibitor (ACE-I), ezetimibe, and n-3 polyunsaturated fatty acid (n-3 PUFA) at FU *p = 0.001, **p < 0.0001 compared with the baseline levels by paired t-test.